Edgewise Therapeutics, Inc.
EWTX
$29.69
-$0.81-2.66%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -167.80M | -157.24M | -150.70M | -146.09M | -133.81M |
| Total Depreciation and Amortization | 2.27M | 2.32M | 2.35M | 2.32M | 2.29M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 27.09M | 23.83M | 21.44M | 17.58M | 12.17M |
| Change in Net Operating Assets | -5.37M | -1.09M | 2.13M | 7.89M | 10.33M |
| Cash from Operations | -143.82M | -132.18M | -124.78M | -118.30M | -109.03M |
| Capital Expenditure | -256.00K | -457.00K | -888.00K | -1.06M | -1.31M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -32.53M | -61.17M | -71.10M | 128.61M | -183.34M |
| Cash from Investing | -32.79M | -61.63M | -71.98M | 127.55M | -184.66M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 196.09M | 195.01M | 196.90M | 10.70M | 249.52M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 0.00 | 0.00 | -214.00K | -300.00K | -262.00K |
| Cash from Financing | 196.09M | 195.01M | 196.68M | 10.40M | 249.25M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 19.48M | 1.20M | -81.00K | 19.66M | -44.43M |